Neonatology
NEONATOLOGY
Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the...
Transplantology
Transplantology – transplantation of organs.
Transplantation of an organ, such as a kidney or a liver, is a life-saving modern treatment of patients whose organs do not function properly for some reason. The effectiveness and safety of organ transplantation is well...
Rare diseases
The term rare applies to those diseases affecting a limited number of people with a prevalence below a given cut-off point, which is codified by the legislation of each individual country. The EU sets this threshold at 0.05% of the population, i.e. one case for every 2,000 inhabitants (in the US a...
Respiratory
Chiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are...
About us
Chiesi Group, one of the world’s leading producers of modern and innovative medical solutions, focuses on several therapeutic areas, including primarily respiratory diseases specialising in the treatment of asthma, cardiovascular diseases, neonatology, musculoskeletal disorders,...
Mission and Values
Our aim is to be recognised as a research-focused international Group, able to develop and commercialise innovative pharmaceutical solutions to improve the quality of human life.
We wish to maintain a high quality entrepreneurial team characterised by self-confidence and a collaborative...
Research and Development
Innovation is the driving force behind every technologically advanced industry, but for the pharmaceutical industry it plays a vital role since it concerns the health and quality of life of people. For Chiesi, Research and Development are a true human and technological asset and, together...
Business responsibility
As a member of the Employers’ Association of Innovative Pharmaceutical Companies INFARMA, CHIESI POLAND is a signatory of:
Code of Good Manufacturing Practice for Pharmaceutical Industry, which sets standards for activities in: promotion and advertisement of medicinal...
Ethics
In order to contribute to common good, ethical behaviour is a fundamental part of CHIESI POLAND’s business activity and expression of its responsibility towards the partners it works with, as well as people who make up the company. Every day, all employees are guided in their actions by...
Transparency
Code of Transparency
Cooperation between medical professionals and healthcare organizations has been a driving force in patient care and the development of innovative medicine for many years. Medical professionals and the affiliated organizations provide the pharmaceutical industry...
What does it mean to be a BCorp? Chiesi's choice for a sustainable future
Since 2017, March has been ‘B Corp Month’, dedicated to celebrating and raising awareness of a young, but already established global movement (the B Corp movement), born out of a revolutionary idea: using business as a force for good.
For centuries, our society has been...
Information on the implemented tax strategy of Chiesi Poland Sp. z o. o.
-
Privacy-SpeakUp&BeHeard
PRIVACY NOTICE
This privacy notice is provided by Chiesi Farmaceutici S.p.A., including its affiliates (together “Chiesi Group“ or “Chiesi”) in compliance with the applicable privacy regulations and is aimed at informing the reporting individuals on how we process...
Chiesi Foundation
Founded in 2005, the Chiesi Foundation Onlus is a no-profit organisation which seeks to capitalise on Chiesi’s legacy of knowledge in order to promote health and alleviate the suffering of patients affected by chronic obstructive respiratory diseases, rare diseases and neonatal diseases. The...
Patient organizations support
By providing patients with modern solutions out of concern for their health, Chiesi Group also supports local activities for education and preventive healthcare carried out by patient organizations and other healthcare stakeholders. Cooperation with patient organizations implies total...
Career
JOB OFFERS:
Information about current recruitment processes are published on the: www.pracuj.pl job advertising service
For more career opportunities at Chiesi: https://careers.chiesi.com/
CAREER at Chiesi:
Development opportunities in Chiesi...
Cookies
For your convenience, the and www.chiesi.pl webpage, hereinafter referred to as the website, uses cookies and similar technologies, in order to adapt the website to user needs, and for statistical purposes. Cookies are small text files sent by the website visited by the Internet user to their...
Office
Chiesi Poland Sp. z o.o.
Aleje Jerozolimskie 134
02-305 Warszawa, Polska
TEL: +48 22 620 14 21
FAX: +48 22 652 37 79
VAT: 527-24-56-136
Trade Register No: 0000223692
Share Capital: 14.000.000 zl
Court Designation: Regional Court for the City of Warsaw in Warsaw, XII Business Department...
Coronavirus
Chiesi Group is closely monitoring the COVID-19 outbreak and is acting in order to make the health and wellbeing of patients and employees a priority. Dedicated teams across our network are taking measures to protect the continuous supply of our medicines in all countries...
Code of Interdependence
Code of Intedependence
Credits
This project was edited and produced by Dynamic Mind.
Chiesi Prescription Products
-
September 12 WE ACT DAY! - We Actively Care for Tomorrow
We do not need to be convinced how important it is to ensure favorable living conditions for the present and future generations and to implement the right to use environmental resources and preserve its value. We hear in the media about the importance of an ecological approach, about non-invasive...
CORPORATE SOCIAL RESPONSIBILITY: COMMUNITY DAY CENTER OF THE CHILDREN'S FRIENDS SOCIETY, UL. GROCHOWSKA 259A IN WARSAW - 10 AUGUST 2018
This year, we have been involved in the voluntary work of Chiesi Poland for the third time. Our activities are in line with the extensive charity work of the entire Chiesi Group.
Let me remind you that our MISSION is to implement among Chiesi Poland employees the idea of sharing their time and...
REDUCTION OF CARBON DIOXIDE EMISSION
Chiesi Poland Sp. z o.o. as a socially responsible company and in accordance with the policy of sustainable development, pay special attention to care for the environment.
As a part of the Chiesi Group, we responded to the global challenge and reduce carbon dioxide emissions. Knowing that...
THE FIRST CHIESI SMILE CONFERENCE
On 9th June 2018 the THE FIRST CHIESI SMILE CONFERENCE was held in Warsaw. There was a lot of fun, joy and laughter – the perfect mix! On Saturday we’ve come to our office accompanied by a quite impressive delegation of young generation. Attractions and surprises were waiting for us...
ECOLOGY
Eurocentrum Office Complex is a green, user-friendly and eco-friendly building, which obtained American LEED CS precertification on the highest PLATINIUM level. (The Leadership in Energy & Environmental Design).
Obtaining such certificate requires substantial involvement during both...
Paolo Chiesi appointed honorary doctor at Karolinska Institute
Paolo Chiesi appointed honorary doctor at Karolinska Institute
Paolo Chiesi receives the award for his long-standing commitment to vital treatment of the lungs of premature babies. The ceremony will take place on 10 May in Stockholm City Hall
Stockholm May 10,...
Chiesi Group is the biggest global pharmaceutical company to become a certified B Corporation
Certified B Corporations meet the highest standards of verified social and environmental performance, transparency and accountability.
Chiesi Group receives the B Corp certification from B Lab, a leading global sustainability non-profit body, in recognition of its corporate sustainability...
First Charity Chiesi Poland Run - EKIDEN 2019
-
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Specialized division focused on research and product development for rare and ultra-rare diseases highlights Chiesi’s commitment to building a brighter future for patients
Chiesi Global Rare Diseases unit will harness the full resources of Chiesi Group to support rare disease communities,...
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
Chiesi Group increases support measures and announces new funds for employees, patients and healthcare providers in response to COVID-19 pandemic
The Group commits €3 million for donations to support the ongoing emergency in Italy
Sustained efforts designed to ensure continuity of...
Chiesi publishes its annual report: Group generates almost €2 billion and obtains B Corp certification in 2019
€1,992.81 million, around 6,000 employees, an 11% reduction in CO2 emissions and more than a fourfold increase in renewable energy consumption – these are some of the Group’s figures;
The report, which is based on the approach of renowned US economist and essayist Jeffrey Sachs, includes...
The B Change: the Instant Book by Pharmastar is online
The Instant Book "Doing business today is also an environmental and social value. The B Change" is online. It has been edited by the editorial staff of Pharmastar and it is dedicated to the international movement of the B Corps. This document is intended to provide a detailed overview of the B Corp...
Chiesi Poland bought Smart Pharma company
Chiesi Poland purchased 100% shares in Smart Pharma company from the investors: funds – YouNick Mint, SpeedUp Innovation (part of SpeedUp Group) and ZYLIOON Invest (ZYLIOON Group) together with the stake of the company of its founder Michał Taisner. After the acquisition Chiesi plans to...
Merging Plan of Chiesi Poland and Smart Pharma
The next step after the purchase of shares is the merger of Chiesi Poland and Smart Pharma. The merger plan was signed today. Click the link below for details.
Merging plan of Chiesi Poland Sp. z o.o. & Smart Pharma Sp. z o.o.
Chiesi Group calls for #ActionOverWords in the fight against climate change
Chiesi Group, the largest international pharmaceutical company certified B Corp, reinforces 2035 carbon neutral target with #ActionOverWords campaign to encourage measurable sustainability commitments and invite accountability.
Parma (Italy), 10 May, 2021 – Chiesi...
Chiesi accelerates path toward full sustainability despite Covid-19 pandemic
Ensuring continuing medical treatment for patients has been top priority during Covid-19 pandemic.
Focus on Diversity & Inclusion in the workplace: 53% of all employees are women – ratio of female workers even higher in R&D (64%).
All the company’s 2020 activities, data and...
Bid aimed to pharmaceutical wholesalers operating on the Polish market
-
Chiesi Poland joins Warsaw Health Innovation Hub
-
What does it mean to be a BCorp? Chiesi's choice for a sustainable future
Since 2017, March has been ‘B Corp Month’, dedicated to celebrating and raising awareness of a young, but already established global movement (the B Corp movement), born out of a revolutionary idea: using business as a force for good.
For centuries, our society has been...
Bramitob®
300 mg /4 ml, nebulizer solution
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which the final decision on the manner and scope of treatment is...
Budiair®
200 micrograms /metered dose, inhalation aerosol, solution
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which the final decision on the manner and...
Budiair® (Jet)
200 micrograms / metered dose, inhalation aerosol, solutionpackage with Jet inhalation chamber
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which...
Curosurf®
80 mg /ml, suspension for intratracheal and bronchoalveolar administrationFraction of phospholipids from the lungs of the pig
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not...
Envarsus®
Envarsus 0.75 mg prolonged-release tabletsEnvarsus 1 mg prolonged-release tabletsEnvarsus 4 mg prolonged-release tablets
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a...
Flamexin®
20 mg, tablets
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which the final decision on the manner and scope of treatment is appropriate.
Fostex®
(100 micrograms + 6 micrograms)/dose, inhalation spray, solutionThe drug is intended for use in adults.
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which...
Peyona®
20 mg/ml, solution for infusion and oral solution
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which the final decision on the manner and...
Atimos®
12 micrograms / metered dose, inhalation aerosol, solution
Therapeutic area: Respiratory
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which...
Trimbow®
87 micrograms + 5 micrograms + 9 micrograms, inhalation spray, solution
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's consultation to which the final decision on the...
Quinsair®
Quinsair® 240 mg, Nebuliser solution
Each mL of nebuliser solution contains levofloxacin hemihydrate equivalent to 100 mg of levofloxacin.
Each ampoule contains 240 mg of levofloxacin.
Formodual
(200 micrograms + 6 micrograms)/inhalation dose, inhalation spray, solutionThe drug is intended for use in adults.
Content on the www.chiesi.pl website is for informational purposes only and can not be considered as a form of medical consultation and may not replace a doctor's...